386 related articles for article (PubMed ID: 33533091)
21. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
Guo L; Feng S; Sun B; Jiang X; Liu Y
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
[TBL] [Abstract][Full Text] [Related]
22. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review.
Huang J; Li T; Tan Z; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Sep; 103():adv13418. PubMed ID: 37731213
[TBL] [Abstract][Full Text] [Related]
24. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
25. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Cheng MW; Kehl A; Worswick S; Goh C
J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
[TBL] [Abstract][Full Text] [Related]
26. Systematic review - alopecia areata and tofacitinib in paediatric patients.
Bandeira A; Albino-Teixeira A; Magina S
Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
[TBL] [Abstract][Full Text] [Related]
27. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata.
Deeb M; Beach RA
J Cutan Med Surg; 2017; 21(6):562-563. PubMed ID: 28635319
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
Asilian A; Mohammadian P; Shahmoradi Z
J Cosmet Dermatol; 2024 Mar; 23(3):886-890. PubMed ID: 37933534
[TBL] [Abstract][Full Text] [Related]
29. Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC; Khanna T; Sallee B; Christiano AM; Bordone LA
Dermatol Ther; 2018 Nov; 31(6):e12656. PubMed ID: 30264512
[TBL] [Abstract][Full Text] [Related]
30. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
31. Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review.
Desai S; Lo K; Nambudiri VE; Villa-Ruiz C; LaChance A; Vleugels RA
Arch Dermatol Res; 2022 Jul; 314(5):487-489. PubMed ID: 33403573
[TBL] [Abstract][Full Text] [Related]
32. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
33. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of tofacitinib in treatment of alopecia universalis in two patients.
Gupta AK; Carviel JL; Abramovits W
J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1373-8. PubMed ID: 27306107
[TBL] [Abstract][Full Text] [Related]
36. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
38. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
39. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
Kołcz K; Żychowska M; Sawińska E; Reich A
Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]